News

Vaccine vs placental malaria
Enlarge image

FundingEUGermanyFranceDenmark

Vaccine vs placental malaria

04.03.2013 - Researchers from the PlacMalVac project have bagged €6m from the EU to start clinical trials of a placental malaria vaccine.

Pregnant women are particularly vulnerable to malaria, due to a particular type of pathology. Their infected blood cells clump together in the placenta, leading to growth retardation and preterm delivery, which in turn cause higher infant mortality. For the first time, a EU consortium of 5 partners led by University of Copenhagen will now begin clinical trials with a vaccine that blocks that blood aggregation in placenta-associated malaria (PAM). It targets the var2CSA protein, which causes aggregation of Plasmodium falciparum-infected erythrocytes by adhesion to the primary placental adherence receptor, chondroitin sulphate A (CSA), present in the placental intervillous blood spaces. Infected mice not carrying var2CSA do not show the PAM-associated effects.

“This will be the first clinical trial using the parasite antigens", said project coordinator Thor G. Theander from the University of Copenhagen. "The vaccine attempts not to eliminate the infection but to eliminate the disease. At Centre for Medical Parasitology we are all thrilled to have this opportunity. It marks an intermediate highpoint of many years of committed research.”

In previous projects supported by the Danish National Advanced Technology Foundation, Theander's team defined a smaller region of multi-domain protein var2CSA. Overall they identified three antigenic regions within it that are crucial for blocking PAM in rats. "We managed proof of concept for the malaria vaccine and we are currently addressing manufacturability of the vaccine. The funding from EU FP7 will enable us to continue the development including upstream and downstream process development, GMP production, Phase Ia and Ib human clinical trials, as well as preparations for Phase II clinical trials."

Theander now heads the EU consortium, which includes University of Copenhagen, ExpreS2ion Biotechnologies (Denmark), Institut de Recherche pour le Développement (France), Université d'Abomey-Calavi (Benin), University of Tübingen and the European Vaccine Initiative (EVI). The EVI has mobilised further €10m for the development of PAM vaccines within the projects PRIMALVAC and PAMCPH.

© eurobiotechnews.eu/tg

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.09 SEK12.50%
  • WILEX (D)2.99 EUR6.79%
  • CO.DON (D)2.75 EUR5.77%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.99 EUR251.8%
  • ADDEX (CH)3.82 CHF59.2%
  • 4SC (D)1.45 EUR49.5%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.72 USD-23.4%
  • PROTHENA PLC (IE)17.37 USD-22.1%

TOP

  • SANTHERA (CH)64.00 CHF3022.0%
  • GW PHARMACEUTICALS (UK)426.00 GBP654.0%
  • PAION (D)2.67 EUR292.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.28 CHF-91.8%
  • THROMBOGENICS (B)9.14 EUR-70.6%

No liability assumed, Date: 29.07.2014